Immunotherapy of myositis: issues, concerns and future prospects

No abstract is available for this paper.

• Publication year

  2010

• Venue

  Nature Reviews Rheumatology

• Publication date

  2010-03-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1038/nrrheum.2010.2PMID 20125096
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Effect of Alemtuzumab (CAMPATH 1-H) in patients with inclusion-body myositis

  2009cited by this paper
• Actualités thérapeutiques dans les polymyosites et dermatomyosites

  2009cited by this paper
• Malignancy Is Associated with Dermatomyositis But Not Polymyositis in Northern New England, USA

  2009cited by this paper
• Oral fingolimod (FTY720) in multiple sclerosis

  2009cited by this paper
• Toxic and drug-induced myopathies

  2009cited by this paper
• B cells as therapeutic targets in autoimmune neurological disorders

  2008cited by this paper
• Interplay between inflammation and degeneration: Using inclusion body myositis to study “neuroinflammation”

  2008cited by this paper
• Correlation of muscle biopsy, clinical course, and outcome in PM and sporadic IBM

  2008cited by this paper
• Alemtuzumab (Campath-1H) for treatment of refractory polymyositis.

  2008cited by this paper
• Case report: successful treatment of posttransplant lymphoproliferative disorder and quiescence of dermatomyositis with rituximab and sirolimus.

  2008cited by this paper
• Interrelation of inflammation and APP in sIBM: IL-1β induces accumulation of β-amyloid in skeletal muscle

  2008cited by this paper
• Idiopathic inflammatory myopathies: Current and future therapeutic options

  2008cited by this paper
• [Current therapy for polymyositis and dermatomyositis].

  2008cited by this paper
• Autoantibodies and their significance in myositis

  2008cited by this paper
• Sporadic inclusion body myositis: a continuing puzzle.

  2008cited by this paper
• A high incidence of disease flares in an open pilot study of infliximab in patients with refractory inflammatory myopathies

  2008cited by this paper
• Inclusion body myositis: current pathogenetic concepts and diagnostic and therapeutic approaches.

  2007cited by this paper
• Plasmacytoid dendritic cells in inflamed muscle of patients with juvenile dermatomyositis.

  2007cited by this paper
• Daclizumab phase II trial in relapsing and remitting multiple sclerosis

  2007cited by this paper
• A pilot trial of rituximab in the treatment of patients with dermatomyositis.

  2007cited by this paper
• Sporadic inclusion body myositis—diagnosis, pathogenesis and therapeutic strategies

  2006cited by this paper
• Therapeutic targets in patients with inflammatory myopathies: present approaches and a look to the future.

  2006cited by this paper
• Mechanisms of Disease: signaling pathways and immunobiology of inflammatory myopathies

  2006cited by this paper
• Mechanisms of Disease: signaling pathways and immunobiology of inflammatory myopathies

  2006cited by this paper
• Treatment of inflammatory myopathies

  2006cited by this paper
• Expression of the β chemokines CCL3, CCL4, CCL5 and their receptors in idiopathic inflammatory myopathies

  2005cited by this paper
• Chronic treatment with folic acid improves endothelial function and decreases superoxide production in human vessels. A double blind placebo control study

  2005cited by this paper
• Interferon‐α/β–mediated innate immune mechanisms in dermatomyositis

  2005cited by this paper
• Rituximab in the treatment of dermatomyositis: an open-label pilot study.

  2005cited by this paper
• A Quantitative Study

  2005cited by this paper
• Immunobiology of muscle: advances in understanding an immunological microenvironment.

  2005cited by this paper
• Interferon-alpha/beta-mediated innate immune mechanisms in dermatomyositis.

  2005cited by this paper
• Inflammatory disorders of muscle: progress in polymyositis, dermatomyositis and inclusion body myositis

  2004cited by this paper
• Steroid-sparing effect of tacrolimus in a patient with juvenile dermatomyositis presenting poor bioavailability of cyclosporine A

  2004cited by this paper
• Intravenous immunoglobulin in autoimmune neuromuscular diseases.

  2004cited by this paper
• Expression and role of novel B7 family members in human muscle: implications for the pathogenesis of inflammatory myopathies

  2004cited by this paper
• Efficacy of tacrolimus in treatment of polymyositis associated with myasthenia gravis

  2004cited by this paper
• Treatment of Dermatomyositis and Polymyositis with Anti-Tumor Necrosis Factor-α: Long-Term Follow-Up

  2004cited by this paper
• Refractory polymyositis responding to infliximab: extended follow-up.

  2004cited by this paper
• Upregulated inducible co-stimulator (ICOS) and ICOS-ligand in inclusion body myositis muscle: significance for CD8+ T cell cytotoxicity.

  2004cited by this paper
• Therapeutic Approaches in Patients with Inflammatory Myopathies

  2003cited by this paper
• Muscle fibres and cultured muscle cells express the B7.1/2-related inducible co-stimulatory molecule, ICOSL: implications for the pathogenesis of inflammatory myopathies.

  2003cited by this paper
• Successful Treatment of Dermatomyositis and Polymyositis with Anti-Tumor-Necrosis-Factor-Alpha: Preliminary Observations

  2003cited by this paper
• Clonal tracking of autoaggressive T cells in polymyositis by combining laser microdissection, single-cell PCR, and CDR3-spectratype analysis

  2003cited by this paper
• Basic principles of immunotherapy for neurologic diseases.

  2003cited by this paper
• Intravenous immunoglobulin for dysphagia of inclusion body myositis

  2002cited by this paper
• Differential expression of chemokines in inflammatory myopathies

  2002cited by this paper
• Idiopathic inflammatory myopathies: epidemiology, classification, and diagnostic criteria.

  2002cited by this paper
• Polymyositis and dermatomyositis

  2002cited by this paper
• Mycophenolate (CellCept) treatment of myasthenia gravis, chronic inflammatory polyneuropathy and inclusion body myositis.

  2001cited by this paper
• High-dose immunoglobulin therapy in sporadic inclusion body myositis: a double-blind, placebo-controlled study

  2000cited by this paper
• Clonal restriction of T-cell receptor expression by infiltrating lymphocytes in inclusion body myositis persists over time. Studies in repeated muscle biopsies.

  2000cited by this paper
• Long term follow up

  1999cited by this paper
• Tacrolimus in refractory polymyositis with interstitial lung disease.

  1999cited by this paper
• Tacrolimus in refractory polymyositis with interstitial lung disease.

  1999cited by this paper
• Sporadic inclusion-body myositis and hereditary inclusion-body myopathies: current concepts of diagnosis and pathogenesis.

  1998cited by this paper
• Immunoglobulin therapy in inflammatory myopathies

  1998cited by this paper
• Treatment of inflammatory myopathies

  1997cited by this paper
• Inclusion body myositis and myopathies

  1997cited by this paper
• Signal transducer and activator of transcription 1 in human muscle: implications in inflammatory myopathies.

  1997cited by this paper
• Treatment of inclusion-body myositis with IVIg

  1997cited by this paper
• Polymyositis with cytochrome oxidase negative muscle fibres. Early quadriceps weakness and poor response to immunosuppressive therapy.

  1997cited by this paper
• Safety and efficacy of strength training in patients with sporadic inclusion body myositis

  1997cited by this paper
• Differential expression of perforin in muscle-infiltrating T cells in polymyositis and dermatomyositis.

  1996cited by this paper
• New Concepts...

  1995cited by this paper
• Expression of cell adhesion molecules in inflammatory myopathies.

  1995cited by this paper
• Immunopathogenesis of inflammatory myopathies

  1995cited by this paper
• T cell receptor repertoire in polymyositis: clonal expansion of autoaggressive CD8+ T cells

  1995cited by this paper
• Inclusion body myositis and myopathies

  1995cited by this paper
• High-dose intravenous immunoglobulin exerts its beneficial effect in patients with dermatomyositis by blocking endomysial deposition of activated complement fragments.

  1994cited by this paper
• Expression of Cell Adhesion Molecules in Inflammatory Myopathies and Duchenne Dystrophy

  1994cited by this paper
• Current treatment of the inflammatory myopathies

  1994cited by this paper
• Acknowledgments

  1993cited by this paper
• Pathology of the inflammatory myopathies.

  1993cited by this paper
• Inclusion Body Myositis: New Concepts

  1993cited by this paper
• A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis.

  1993cited by this paper
• Controlled trial of plasma exchange and leukapheresis in polymyositis and dermatomyositis.

  1992cited by this paper
• Polymyositis, dermatomyositis and inclusion-body myositis.

  1991cited by this paper
• Amyloid filaments in inclusion body myositis. Novel findings provide insight into nature of filaments.

  1991cited by this paper
• Inclusion body myositis with cricopharyngeus muscle involvement and severe dysphagia

  1991cited by this paper
• Microvascular changes in early and advanced dermatomyositis: A quantitative study

  1990cited by this paper
• Major histocompatibility complex class I antigen expression, immunolocalization of interferon subtypes, and T cell-mediated cytotoxicity in myopathies.

  1989cited by this paper
• Expression of immunoreactive major histocompatibility complex products in human skeletal muscles

  1988cited by this paper
• Mononuclear cells in myopathies: quantitation of functionally distinct subsets, recognition of antigen-specific cell-mediated cytotoxicity in some diseases, and implications for the pathogenesis of the different inflammatory myopathies.

  1986cited by this paper
• Microvascular deposition of complement membrane attack complex in dermatomyositis.

  1986cited by this paper
• Monoclonal antibody analysis of mononuclear cells in myopathies. III: Immunoelectron microscopy aspects of cell‐mediated muscle fiber injury

  1986cited by this paper
• Monoclonal antibody analysis of mononuclear cells in myopathies. I: Quantitation of subsets according to diagnosis and sites of accumulation and demonstration and counts of muscle fibers invaded by T cells

  1984cited by this paper
• Prednisone and azathioprine for polymyositis: long-term followup.

  1981cited by this paper

• Immunotherapies in autoimmune inflammatory myopathies: Rationale and therapeutic updates.

  2026cites this paper
• Clinical Progress in Mesenchymal Stem Cell Therapy: A Focus on Rheumatic Diseases

  2025cites this paper
• Mutual reinforcement of lymphotoxin-driven myositis and impaired autophagy in murine muscle

  2025cites this paper
• Telitacicept add-on therapy in refractory idiopathic inflammatory myopathy: insights from a pilot study.

  2024cites this paper
• Modulation of mitochondrial activity by sugarcane (Saccharum officinarum L.) top extract and its bioactive polyphenols: a comprehensive transcriptomics analysis in C2C12 myotubes and HepG2 hepatocytes

  2024cites this paper
• Combination of transarterial radioembolization with atezolizumab and bevacizumab for intermediate and advanced staged hepatocellular carcinoma: A preliminary report of safety and feasibility

  2023cites this paper
• Idiopathic inflammatory myopathies - The burden of disease: Cohort analysis focusing on damage and comorbidities.

  2023cites this paper
• Dermatomyositis with Eosinophils

  2023cites this paper
• Dermatomyositis Diagnosis and Treatment in the Inpatient Setting

  2023cites this paper
• Muscle glycome in idiopathic inflammatory myopathies: Impact in IL-6 production and disease prognosis

  2023cites this paper
• Autoimmune inflammatory myopathies.

  2023cites this paper
• Identification of hub biomarkers and immune cell infiltration characteristics of polymyositis by bioinformatics analysis

  2022cites this paper
• Update on Paraneoplastic Neuromuscular Disorders

  2022cites this paper
• Knee Arthrodesis for Mycobacterium avium Complex Native-Knee Septic Arthritis in a Patient with Dermatomyositis

  2022cites this paper
• Iron controls T helper cell pathogenicity by promoting glucose metabolism in autoimmune myopathy

  2022cites this paper
• Management of dermatomyositis patients amidst the COVID-19 pandemic: Two case reports

  2022cites this paper
• Response to cyclophosphamide and rituximab therapy in idiopathic inflammatory myopathies: A single center experience

  2021cites this paper
• Treatment of Active Idiopathic Inflammatory Myopathies by Low-Dose Interleukin-2: A Prospective Cohort Pilot Study

  2021cites this paper
• Rituximab in the treatment of immune-mediated necrotizing myopathy: a review of case reports and case series

  2021cites this paper
• A systematic review of physical exercise for patients with idiopathic inflammatory myopathies.

  2021cites this paper
• The Immunomodulatory Function of Vitamin D, with Particular Reference to SARS-CoV-2

  2021cites this paper
• Dermatomyositis and Other Autoimmune Disorders

  2021cites this paper
• Immunotherapy – A Novel Facet of Modern Therapeutics

  2021cites this paper
• Dermatomyositis. Diagnostic and therapeutic recommendations of the Polish Dermatological Society

  2021cites this paper
• Vitamin D, Its Role in Recovery after Muscular Damage Following Exercise

  2021cites this paper
• Role of Immunoglobulins in Muscular Dystrophies and Inflammatory Myopathies

  2021cites this paper
• MicroRNA-409-3p regulates macrophage migration in polymyositis through targeting CXCR4

  2021cites this paper
• Supervised Physical Therapy and Polymyositis/Dermatomyositis—A Systematic Review of the Literature

  2020cites this paper
• Inflammatory myopathies: update on diagnosis, pathogenesis and therapies, and COVID-19-related implications

  2020cites this paper
• Future Immunotherapy Challenges and Perspectives

  2020cites this paper
• Reduced miR-146a Promotes REG3A Expression and Macrophage Migration in Polymyositis and Dermatomyositis

  2020cites this paper
• Dermatomyositis Part I: Clinical Features and Pathogenesis.

  2020cites this paper
• Nrf2/ARE pathway inhibits inflammatory infiltration by macrophage in rats with autoimmune myositis

  2019cites this paper
• [Idiopathic inflammatory myopathies. A review].

  2019cites this paper
• Polymyositis and dermatomyositis – challenges in diagnosis and management

  2019cites this paper
• Physical therapy in adult inflammatory myopathy patients: a systematic review

  2019cites this paper
• Efficacy and patient satisfaction in the use of subcutaneous immunoglobulin immunotherapy for the treatment of auto-immune neuromuscular diseases.

  2018cites this paper
• Immune Mediated Necrotizing Myopathy: Where do we Stand?

  2018cites this paper
• Interleukin-37 (IL-37) Suppresses Pertussis Toxin-Induced Inflammatory Myopathy in a Rat Model

  2018cites this paper
• JAK inhibitor improves type I interferon induced damage: proof of concept in dermatomyositis

  2018cites this paper
• Statin‐associated immune‐mediated necrotising myopathy: a New Zealand case series showing possible overrepresentation in Pacific Islanders

  2018cites this paper
• Treatment consensus for management of polymyositis and dermatomyositis among rheumatologists, neurologists and dermatologists

  2018cites this paper
• Assessment of renal function in patients with myositis and treated with subcutaneous immunoglobulin: a series of 24 cases

  2018cites this paper
• Recent developments on treatment strategies and the prognosis of dermatomyositis: a review

  2018cites this paper
• Idiopathic Inflammatory Myopathies

  2018cites this paper
• Dermatomyositis und andere Autoimmunerkrankungen

  2018cites this paper
• Rituximab in the treatment of inflammatory myopathies: a review.

  2017cites this paper
• Entzündliche Muskelerkrankungen – Aktueller Stand zur Diagnostik und Therapie der Myositis

  2017cites this paper
• 10 Immunoglobulin Treatment in Polymyositis and Dermatomyositis

  2017influential citation
• Corticosteroids Treatment in Spinal Cord and Neuromuscular Disorders

  2017cites this paper
• Animal models in idiopathic inflammatory myopathies: How to overcome a translational roadblock?

  2017cites this paper
• Efficacy and safety of adrenocorticotropic hormone gel in refractory dermatomyositis and polymyositis

  2017cites this paper
• 3-n-Butylphthalide reduces the oxidative damage of muscles in an experimental autoimmune myositis animal model

  2017cites this paper
• Vitamin D in autoimmune rheumatic diseases: A view inside gender differences

  2017cites this paper
• Medical resource utilization in dermatomyositis/polymyositis patients treated with repository corticotropin injection, intravenous immunoglobulin, and/or rituximab

  2017cites this paper
• Long-term subcutaneous immunoglobulin use in inflammatory myopathies: A retrospective review of 19 cases.

  2016cites this paper
• Entzündliche Muskelerkrankungen – Aktueller Stand zur Diagnostik und Therapie der Myositis

  2016cites this paper
• État des lieux des myopathies inflammatoires de l'adulte à travers leur prise en charge diagnostique et évolutive au centre hospitalo-universitaire d'Amiens ces dix dernières années

  2016cites this paper
• Immune-Mediated Myositis in Horses: From phenotype to genotype

  2016influential citation
• The Spectrum of Inflammatory Myopathies: Dermatomyositis, Polymyositis, Necrotizing Myositis, and Inclusion-Body Myositis

  2016cites this paper
• H.P. Actharî Gel in Dermatomyositis and Polymyositis TreatmentRegistry: An Interim Analysis

  2016cites this paper
• Autoimmune Myopathies: Where Do We Stand?

  2016cites this paper
• Economic Evaluation of Intravenous Immunoglobulin plus Corticosteroids for the Treatment of Steroid-Resistant Chronic Inflammatory Demyelinating Polyradiculoneuropathy in Thailand

  2016cites this paper
• Repository Corticotropin Injection for Treatment of Idiopathic Inflammatory Myopathies

  2016cites this paper
• Immune-mediated necrotizing myopathy

  2016cites this paper
• Current pharmacological treatment of idiopathic inflammatory myopathies

  2016cites this paper
• H.P. Acthar® Gel in Dermatomyositis and Polymyositis Treatment Registry: An Interim Analysis

  2016influential citation
• MiR-146a Regulates Inflammatory Infiltration by Macrophages in Polymyositis/Dermatomyositis by Targeting TRAF6 and Affecting IL-17/ICAM-1 Pathway

  2016cites this paper
• Diagnostic performance of a commercial immunoblot assay for myositis antibody testing.

  2016cites this paper
• Etat des lieux des myopathies inammatoires de l'adulte a travers leur prise en charge diagnostique et evolutive au centre hospitalo-universitaire d'Amiens ces dix

  2016cites this paper
• The identification of nuclear receptors associated with hepatic steatosis to develop and extend adverse outcome pathways

  2016cites this paper
• Autoantibodies and the type I interferon system in idiopathic inflammatory myopathies

  2016cites this paper
• Inflammatory muscle diseases.

  2015cites this paper
• Development of an improved animal model of experimental autoimmune myositis.

  2015cites this paper
• Future perspectives in target-specific immunotherapies of myasthenia gravis

  2015cites this paper
• Sporadic inclusion-body myositis: A degenerative muscle disease associated with aging, impaired muscle protein homeostasis and abnormal mitophagy.

  2015cites this paper
• Interleukin-1 receptor antagonist for refractory anti-MDA5 clinically amyopathic dermatomyopathy.

  2015cites this paper
• Recent Treatment of Interstitial Lung Disease with Idiopathic Inflammatory Myopathies

  2015cites this paper
• Cost-Utility Analysis of Intravenous Immunoglobulin for the Treatment of Steroid-Refractory Dermatomyositis in Thailand

  2015cites this paper
• Acquired neurocutaneous disorders.

  2015cites this paper
• An overview of polymyositis and dermatomyositis

  2015cites this paper
• Skeletal muscle interleukin 15 promotes CD8+ T-cell function and autoimmune myositis

  2015cites this paper
• Applying complement therapeutics to rare diseases.

  2015cites this paper
• The injury-induced myokine insulin-like 6 is protective in experimental autoimmune myositis

  2014cites this paper
• Biologics in polymyositis and dermatomyositis-associated interstitial lung disease.

  2014cites this paper
• Molecular mechanisms in idiopathic inflammatory myopathies

  2014cites this paper
• Common and distinct immunological aspects in acquired inflammatory myopathies and inherited muscular dystrophy

  2014cites this paper
• Vitamin D Receptor Agonists: Suitable Candidates as Novel Therapeutic Options in Autoimmune Inflammatory Myopathy

  2014cites this paper
• A review on the association between inflammatory myopathies and vaccination.

  2014cites this paper
• Subcutaneous immunoglobulin G in idiopathic inflammatory myopathies: therapeutic implications.

  2014cites this paper
• Idiopathic inflammatory myopathies.

  2014cites this paper
• Immunotherapy in the Treatment of Autoimmune Neuromuscular Diseases

  2014cites this paper
• 2 Sporadic inclusion-body myositis: A degenerative muscle disease 3 associated with aging, impaired muscle protein homeostasis and

  2014cites this paper
• [Biologic therapy in idiopathic inflammatory myopathy].

  2014cites this paper
• T CELL SUBSETS AND DISEASE MECHANISMS IN INFLAMMATORY MYOPATHIES

  2014cites this paper
• Long-term efficacy of alemtuzumab in polymyositis

  2014cites this paper
• An analysis of the sensitivity and specificity of MHC-I and MHC-II immunohistochemical staining in muscle biopsies for the diagnosis of inflammatory myopathies.

  2014cites this paper
• A fatal presentation of dermatomyositis.

  2013cites this paper
• Autoantibodies to cytosolic 5′‐nucleotidase 1A in inclusion body myositis

  2013cites this paper
• Novel future therapeutic options in myasthenia gravis.

  2013cites this paper